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A brief survey is provided of common designs for medical studies and
important issues in their implementation. The designs discussed
include those for laboratory studies, clinical trials, cohort studies,
case-control and related studies, and diagnostic studies.
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Introduction
The value of a medical study, which we take to be any human
health related investigation, depends primarily on the value of
the question or questions the study aims to answer and the
informativeness of the available data for answering these ques-
tions. Both these criteria are strongly influenced by study design.
This article aims to provide an overview of the design of medical
studies, excluding sample surveys, and of some important issues
in planning such studies. There are often overarching consider-
ations of ethics and simplicity that limit what is possible and
therefore make it difficult to be prescriptive about what is a good
study. Nevertheless, an understanding of general aspects of study
design should underlie the planning of any study.
Distinction can be made between clinical and epidemiological
studies. The former would often be concerned with the treatment
of patients and the latter with “the variation in disease occur-
rence and the reasons for that variation”.1 However, this
distinction can become blurred and, in recent years, the field of
clinical epidemiology has also emerged, defined by Weiss2 as
“the study of variation in the outcome of illness and of the rea-
sons for that variation”. In addition, some laboratory studies may
not be felt to fall in any of these categories. Another helpful and
important distinction is between observational and experimental
studies but there are many possible study types that fall between
these categories. For the purposes of this article, we will consider
only the most common types of studies. For each, we describe
the nature of data collection, which will largely make the
observational and experimental distinction, and the type of
questions being addressed.
The primary designs to be discussed will be for:
1. Laboratory studies
2. Clinical trials
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5. Diagnostic studies
Types of outcomes and regression modelsOutcomes
For any study, there is usually a primary outcome, or response,
of interest. These may take a variety of forms but common types
are:
a. A continuous measurement, e.g. blood pressure, antibody
level
b. A yes/no (binary) indicator, e.g. disease versus no disease,
relapse versus no relapse
c. The time to an event, e.g. time to death, time to disease
d. A count variable, e.g. number of cells, number of
metastases.Regression models
For a continuous measurement, it is often assumed that the
outcome, Y, follows a normal distribution, perhaps after a
transformation of some kind. Analysis will focus on modelling
the average or expected value of Y, E(Y), under different condi-
tions. The most common basis is a regression model which as-
sumes that
E(Y) ¼ a þ b1X1 þ b2X2 þ . þ bkXk
where the Xis represent explanatory variables that code infor-
mation on study subjects such as treatment or exposure received,
age, etc. and the b values are to be estimated and represent the
effect of the factor coded by the X variable on Y, all else being
equal. In the simple case where (say) X1 takes the value 0 for a
subject receiving treatment T1 and 1 for a subject receiving T2,
and there are no other explanatory variables, then b1 will esti-
mate the difference in E(Y) between a subject receiving T2 and
one receiving T1. If there are other explanatory variables in the
model, then b1 has the same interpretation but under the addi-
tional assumption that all other explanatory variables are the
same for the two subjects.
When Y is binary (either 0 or 1), then the regression
approach can model the logarithm of the odds of Y ¼ 1 versus
Y ¼ 0, [Pr(Y ¼ 1)/Pr(Y ¼ 0)], and, in the case of a binary
treatment/exposure indicator X1, b1 will represent the loga-
rithm of a ratio of the odds of Y ¼ 1 for treatment T2 with the
odds for treatment T1, a so-called odds ratio. This methodology
is termed logistic regression.
When interest is in a time to event outcome, a regression
model will typically be developed for a rate or risk function, r(t),
which may depend on time in some fashion. Typically log[r(t)] is
modelled and then b1 will represent a relative rate function
comparing, for example, the rate for subjects receiving T2 with
those receiving T1. This is a comparison, for the two treatments,
of the probability of an event occurring at time t given that it has
not occurred previously. For more details, see the paper on
survival analysis in this issue.3
A regression model for a count variable will typically model
the logarithm of the average count per unit of time or space
which is also a form of rate function. The coefficient b1 would
then be the logarithm of a relative rate comparing the count rate
in subjects receiving T2 with those receiving T1. The most 2016 The Authors. Published by Elsevier Ltd. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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distribution assumed for the count variable. Further discussion of
these methods can be found in the article on Regression in this
issue.4Confounding
Regression models, and related analyses, that allow explanatory
variables for more than one factor are particularly valuable in
dealing with confounding. Confounding arises when an additional
factor is related both to an outcome variable and an explanatory
factor of primary interest, i.e. treatment or exposure. If this addi-
tional factor is not adjusted for in an analysis, often by inclusion in
a regression model, then any estimate of the relationship between
the outcome and the primary factor may be biased.
Laboratory studies
The amount of investigator control possible strongly influences
study design. Substantial control is often possible in laboratory
studies in terms of the number of observations taken and the
experimental conditions. An extensive literature on ‘experi-
mental design’ assumes this control and considers quite complex
designs. Here, only basic structures are presented to introduce
some concepts relevant to many study designs.
For concreteness, assume a study is to compare two treatments,
T1 andT2, and that there is an outcomeof interest, e.g. ameasure of
cell growth, denoted Y. The primary focus of the study will be to
compare the expected or average value of Y for cells receiving T1
with those receiving T2. Additionally, assume that there may be
another factor of importance that might influence Y, and, again for
concreteness, assume this is a simple two way classification, S1
and S2, for example, two laboratory technicians.
Table 1 displays two rather idealised study designs, I and II,
assuming the use of 100 well test plates. The first plate of design I
itself represents a simple design. If interest is restricted to ob-
servations in class S1, then a comparison of T1 and T2 could be
based on comparing Y values for the 50 wells on Plate 1 receiving
T1 and the 50 wells receiving T2. The precision with which the
averages, or expected values, of Y for wells receiving T1 and T2
can be determined will depend on the number of wells receiving
each treatment. This is often termed replication and is a central
feature of any study design. The observed average values in the
two groups will be compared and the replication will provide a
measure of the variation in Y against which any difference in the
averages can be assessed.
More generally in a study of design I, there will be separate
groups of observations in the same class, either S1 or S2, andObservation numbers in two basic design structures
I II
T1 T2 T1 T2
S1 Plate 1 50 50 100 0
Plate 2 50 50 0 100
S2 Plate 3 50 50 100 0
Plate 4 50 50 0 100
Table 1
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tions receiving T1 and T2. Within a class, a comparison of Y
values for the two treatments can be made and the information
from these comparisons is combined across the different classes
to give an overall estimate of how Y depends on the treatment
received. The simplest design of this type would be represented
by the observations from Plates 1 and 3 of design I. The four rows
of design I represent a situation that also allows estimation of the
dependence of Y on the S1/S2 classification. This would be ach-
ieved by averaging the Y values for each plate and evaluating the
average of these averages in the two rows corresponding to each
class in light of the variation of the averages in plates with the
same classification.
Design II represents the situation when a study design re-
quires that all subjects in a defined group receive the same
treatment. In our example, this might correspond to radiation or
no radiation of plates. The comparison of T1 and T2 must then be
made between plates. Thus the average value of Y in Plate 1 can
be compared with the average value in Plate 2, both being
observed in class S1, and similarly the average values in Plates 3
and 4 can be compared. The replication in this design comes
from having multiple plates for which an average value of Y can
be determined.
Table 1 is idealised and the simple averaging of Y values dis-
cussed is only generally appropriatewith highly ‘balanced’ designs
as in Table 1. However, the general principles are applicable to
more complicated situations through the use of regression models
which also provide suitable measures of variability. A more
comprehensive discussion of measures of variability, and how
they are reflected in designs such as I and II, is provided in the
paper on Components of Variance in this issue.5
Clinical trialsGeneral background
The usual aim of a clinical trial is to evaluate a new treatment for
some disease or compare alternative treatments or treatment
strategies. Obviously, a good clinical trial should seek to answer
an interesting question. The choice of treatments to be compared
and the patients on whom they are to be compared largely
characterize this. Strict entrance requirements that generate a
homogeneous patient population facilitate precise treatment
comparisons. However, the use of a more heterogeneous popu-
lation may be more practically relevant and convincing. The
comparison of two highly divergent treatments is simple and
likely to produce a result more quickly than a comparison of two
similar treatments, or a trial involving more than two treatments.
However, more complex designs may allow a more compre-
hensive set of questions to be addressed. Of course, treatments
must also be acceptable to clinicians who must enter their pa-
tients into the trial.
Traditionally, clinical trials have been classified in terms of
their developmental stage as phase I, II, III or IV; these labels
derive primarily from drug development. In this context, phase I
trials are primarily dose-finding, phase II studies provide a pre-
liminary investigation of efficacy, phase III designs compare new
treatments with standard therapy or no therapy, and phase IV
investigations relate to post-marketing surveillance. We focus on
comparative trials here. 2016 The Authors. Published by Elsevier Ltd. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The size of a study determines the precision with which ques-
tions can be answered. This section is relevant to all studies but
sample size is particularly important in clinical trials because it
also has ethical implications. Formal sample size calculations
will typically address one of two design questions:
a. How many subjects are needed?
b. Is the study worth doing if only a specific number of subjects
are available?
Such calculations are, it must be remembered, almost always
approximate and may not reflect the entire complexity of a
design. However, they will be typically based on some primary
effect measure such as an estimate of a difference in means, a
relative risk or an odds ratio. The variance of this estimated
measure will typically be of a form s2/n, where n is the number
of subjects in the study and s2 is determined by the particular
effect measure of interest and the variability expected in the
outcome measure of interest, the latter usually based on prior
data and/or publications. Thus precision will increase, i.e. the
variance will decrease, as n is increased.
It is often reasonable, and simplest, to determine a planned
sample size based on this measure of precision. However, the
concept of the power of a study is also widely used. Statistical
power is defined as the probability of detecting a designated ef-
fect when testing at a specific significance level. Significance
testing is discussed in a paper in this issue.6 Briefly, a signifi-
cance test will assess whether there is a non-zero effect of a
treatment or exposure on the outcome of interest and will be
associated with a particular level of significance, often 5%. This
stipulates that an investigator will accept no more than a 5%
chance of concluding an effect exists when, in fact, there is no
effect, i.e. the false positive rate. Power can be viewed as one
minus the false-negative rate for a statistical test.
A power calculation thus requires specification of a signifi-
cance testing level, together with two of (1) the effect size of
medical importance, (2) the power desired and (3) the sample
size, the remaining element then being the result of the calcu-
lation. The convention, that failure to reject the null hypothesis
of no effect is equivalent to concluding that the null hypothesis is
true, is inappropriate at the time of analysis but this decision
making structure is convenient for power calculations.
It has recently been encouraged, or required, to specify power
calculations when reporting study results. One motivation is to
consider the magnitude of effect that might have been missed in a
‘negative’ study. However, this is better addressed through confi-
dence intervals that reflect theuncertainty attached toanyestimated
effect. For example, if an effect of interest lies outside a 95% con-
fidence interval for the estimated effect, then it is unlikely to exist
whereas if it is in the interval then it cannot be ruled out. As Cox7
writes, power is “quite irrelevant in the actual analysis of data”.Treatment assignment
Treatment assignment in a trial is often stratified to guarantee
demonstrable balance across one or more known prognostic
factors. These factors are used to define separate groups of pa-
tients within each of which a balance of treatment assignments is
desired. Since this balance ensures these factors are not related to
treatment assignment, they cannot confound any estimated
treatment effect. However, excessive stratification can beDIAGNOSTIC HISTOPATHOLOGY 22:7 248complex and even lead to poor balance if strata are too small. So
it is sensible to stratify on only a few major factors. Approximate
balance on other factors is maintained through random treatment
assignment, crucially also providing protection against unmea-
sured confounding factors.
An alternative to stratification is minimization. Minimization
avoids the potential problems of stratification with a large
number of factors, provided cross-classification of the factors is
not thought important. Rather than aiming for balance in each
stratum defined by the combination of the prognostic factors,
minimization ensures, when each prognostic factor is examined
individually, that there is appropriate balance between treatment
assignments. Unlike stratification, treatment allocation rules
cannot be determined in advance of the study and therefore
practical procedures for allocation are more complicated.
When designing a trial, it is increasingly required to specify
the statistical procedures intended for the analysis of the trial
through a‘statistical analysis plan’. This ensures that in-
vestigators think about the primary and secondary outcomes of
interest and the specific treatment comparisons of interest. This
also avoids a‘search for significance’ by examining many
different comparisons based on a variety of outcomes and
various subsets of the patient population. However, as argued by
Cox and Donnelly,8 the trial data, when available, may suggest
that additional or alternative analyses could be appropriate and
informative. If this leads to a radical change in trial objectives
then confirmatory studies will likely be needed. However, as Cox
and Donnelly write, “while an initial plan of analysis is highly
desirable, keeping at all cost to it alone may well be absurd”
because it unduly limits the information available from the
study.Intention to treat
All patients in a trial should ideally be followed, even if they
abandon the treatment protocol. Exclusion of these patients can
introduce bias if their failure to complete the protocol is linked to
the outcome of treatment. Similarly, the primary analysis should
usually compare groups based on originally assigned treatments
to assess how they will perform in general use. This is termed an
‘intention to treat’ analysis. It may be of interest to restrict a
comparison to those patients receiving and tolerating treatment
regimens, addressing the question of ‘the effect of the treatment
on the treated’, but the case for such comparisons should be
carefully argued (See Matthews and Farewell,9 Chapter 18). Note
that, in order to avoid bias, treatment assignment should only
occur after informed consent procedures. Otherwise, the treat-
ment assigned may influence whether a patient agrees to enter
the trial making the treatment groups less comparable.Randomization
A randomized clinical trial, in which a patient’s treatment is
randomly chosen and not therefore predictable, is generally
regarded as the best form of evidence. The advantages of a
randomized comparison are summarized by Cox7 as:
(a) an assurance that in a large experiment it is very unlikely
that the estimated treatment effects will be appreciably in
error; and
(b) an assurance that the random error of the estimated treat-
ment effects can be measured. 2016 The Authors. Published by Elsevier Ltd. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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that a group of patients on one treatment is observed to do
better than a corresponding group on an alternative treatment is
of value only if it can then be declared that the observed dif-
ference is attributable solely to the two treatments and not to
something else. Thus, randomization can be seen as the means
to establish that treatment caused the difference observed. In
this regard, approaches such as alternating treatment assign-
ment might be equally effective; however, randomization
additionally prevents deliberate or accidental interference in
treatment assignments.
A proposed alternative to randomization is the use of ‘his-
torical controls’ from previous studies of the same population of
patients. The use of these might be of value in some settings, say
in early stage trials, but the arguments for their use are much
more complex for comparative trials. Deeks et al.10 reviewed this
question and concluded:
“Results of non-randomized studies sometimes, but not al-
ways, differ from results of randomized studies of the same
intervention. Non-randomized studies may still give serious
misleading results when treated and control groups appear
similar in key prognostic factors. Standard methods of case-mix
adjustment do not guarantee removal of bias. .
The inability of case-mix adjustment methods to compensate
for selection bias and our inability to identify non-randomized
studies that are free of selection bias indicate that non-random-
ized studies should only be undertaken when randomized
controlled trials are infeasible or unethical.”Factorial designs
Many clinical trials are designed, primarily, to answer a single
question. This may be an unnecessary or even unhelpful re-
striction. For example, for diseases that require multi-modal
therapy, a trial may compare alternative treatments within
each mode. This represents a factorial design and may make
better use of resources or even be essential to appropriately
evaluating treatment choices.Sequential clinical trials
During a clinical trial, it is common, and often ethically
mandated, to prepare interim analyses of accrued data. If one
treatment can be shown to be superior, then it is necessary to
stop the trial so that all patients may receive the optimal
treatment. Unfortunately, the more frequently the study data
are examined, the more likely it is that a ‘statistically signifi-
cant’ result will be observed even if there is no difference be-
tween the treatments. For example a single test may have a 5%
chance of a false-positive result. However, if five such tests are
done, then the chance of at least one of the tests being positive
is 14.2%.
This phenomenon has led to specialized techniques to
‘monitor’ clinical trials. Fleming et al.11 argue that treatment
differences observed in the early stages of a trial may occur for a
variety of reasons, and that the primary purpose of a sequential
design is to protect against unexpectedly large treatment dif-
ferences. Therefore, Fleming et al. advocate using group
sequential designs based on scheduled repeated analyses that do
this but preserve sensitivity to late-occurring survival
differences.DIAGNOSTIC HISTOPATHOLOGY 22:7 249Equivalence trials
A trial to test the equivalent efficacy of two treatments, say
because a new treatment is expected to have lower toxicity or
cost than a current treatment, cannot be based on a failure to
reject a significance test because this does not establish equiva-
lence. Thus, equivalence trials are generally designed to establish
that the relative efficacy between two treatments does not exceed
some specific, usually clinically unimportant, level.
Essentially, the trial will be designed to provide a confidence
interval for the relative efficacy that is small enough to rule out
unacceptably large differences. If it is only knowledge that a new
treatment is no worse than a standard that is of interest, then the
term ‘non-inferiority trial’ is used.Other designs
The most common design for a clinical trial is the so-called
parallel group design where patients are individually random-
ized. Two more complex designs are cross-over trials and cluster
randomized studies.
Cross-over designs can be used when patients can be treated
sequentially with more than one treatment. For example,
different symptomatic treatments for asthma could be made
available to a patient during successive months. If two treat-
ments, say A and B, are under study and two time periods will be
used, then the classic two-period cross-over design would enrol
patients and then randomly assign them to receive treatments in
the order AB or BA.
The potential advantage of a cross-over design is that treat-
ments can be compared within patients rather than between
patients, usually leading to more precise comparisons. However,
if the effect of treatments might ‘carry-over’ from one period to
the next, then a cross-over design is not recommended. Exten-
sions to more than two periods are possible.
Cluster randomized trials, or group randomized trials, arise
when randomization of individual patients is not possible or
inconvenient. For example, varying the treatment provided from
patient to patient within the same medical centre or practice
might be difficult or an educational intervention may be designed
for a classroom setting. In such cases, a group of study subjects
are effectively randomized together to the same intervention.
In such trials, the analysis must compare treatments at the
level of randomization and allow for correlation between out-
comes for subjects randomized together, arising because these
outcomes will be more similar than those for patients in different
clusters. A common approach to the analysis of such trials is to
use random effects models. (See paper on components of vari-
ance in this issue5). It is critical not to ignore the clustering
because this design will provide less precise estimates of treat-
ment effects than those available from a comparably sized indi-
vidually randomized trial.
Cohort studies
In a cohort study, a population or random sample of a population is
monitored longitudinally for a period of time. Important character-
istics of each cohortmember are ascertained at the start of the study,
or when a subject ‘enters’ the cohort, and during the period of
follow-up. This information is used to define the explanatory vari-
ables or ‘risk factors’ that may be related to outcomes of interest. 2016 The Authors. Published by Elsevier Ltd. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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spectively, that is, before the outcome is observed. However,
some or all risk factor information, or indeed outcome informa-
tion, may not necessarily be acquired at the time of measure-
ment. A distinction is therefore sometimes made between
retrospective, or historical, cohort studies and prospective cohort
studies. A prospective cohort follows each individual and ac-
quires information after the individual agrees to enter the study.
In the classical historical cohort study, the period of follow-up
has usually occurred before the study is undertaken. Essen-
tially the study is a reconstruction of past events. This may be
cheaper and faster than a prospective cohort study but depends
on having accurate exposure data on subjects during the past,
avoiding issues such as recall bias, and accurate follow-up data
on virtually all subjects. Of course, there can be a range of
variation between these two extremes when some information is
acquired retrospectively and other prospectively. However, once
appropriate data are acquired, by whatever means, the analysis
would proceed as if the data were acquired prospectively.Epidemiological cohort studies
The cohort study is a primary tool for the study of disease inci-
dence, importantly providing a direct estimate of the rate of
disease incidence in population subgroups defined by the
explanatory variables.
As well as through the prospective/retrospective data collec-
tion distinction, epidemiological cohort studies can also be
distinguished by whether they have an internal or external con-
trol group who do not experience an exposure of interest. An
internal control group arises when study subjects include unex-
posed individuals. If such a group is not present, for example in a
study of workers with a common occupational exposure, then
study subjects may be compared with an external standard. This
might be derived from national mortality or morbidity data, but
may not be appropriate for all purposes. For example, the so-
called ‘healthy worker effect’ suggests that employed in-
dividuals will be, on average, healthier than the general working
age population and thus there is a bias against detecting adverse
conditions when comparing an occupational cohort to national
age-specific data. Comparisons within the cohort are generally to
be preferred and an important design criterion is to ensure there
is sufficient detail on individual exposures to allow detailed
analysis of differential exposure levels.
Prospective epidemiological cohort studies are subject to the
limitation that the information collected is determined when the
study is initiated. Typically there will be a few major outcomes
that will be monitored and the explanatory variable information
will reflect what is known about possible disease risks. During
the course of the study, other information may suggest other
outcomes or other risk factors might be of interest. It is generally
difficult to compensate for this by additional retrospective data
collection.Clinical cohort studies
A clinical cohort typically derives from longitudinal follow-up of
patients with a specific disease. Much more commonly than in
epidemiological cohorts, patients will enter the cohort over a
considerable period of time, the recruitment period. The basic
data structure is the same as that for an epidemiological cohortDIAGNOSTIC HISTOPATHOLOGY 22:7 250but the outcomes of interest will now typically be disease related
outcomes. Also, the risk factors of interest will generally be based
on clinical/laboratory/genetic information as well as de-
mographic factors. For example, based on a clinical cohort of
carefully followed rheumatoid arthritis patients, a question of
interest might be whether pain in joints leads to permanent
damage in those joints or, alternatively, what aspects of the
disease course are most related to a patient’s quality of life.
Often a clinical cohort will aim to begin to follow patients as
soon as they are diagnosed with a condition. This would create
an ‘inception cohort’. For some diseases, it may be quite
straightforward to contact patients at this point. For example,
this is often the case with cancer diagnoses. However, in other
cases, such as rheumatological diagnoses, it may be much more
difficult. Many cohorts are based on patients referred to tertiary
treatment centres and these patients may come for treatment at
any stage of disease. Nevertheless, important information on
disease course can derive from non-inception cohorts. In addi-
tion, an inception sub-cohort can sometimes be identified from a
larger cohort.
Case-control and related studies
The collection of cohort data is time-consuming and expensive.
This is particularly true in the case of epidemiological in-
vestigations of rare diseases and, therefore, a very important
study design in epidemiology is the case-control study, which
might equally be termed a case-noncase study. This involves the
selection of a random sample of incident cases of the study dis-
ease in a defined population during a specified case accession
period. Corresponding comparison individuals (the noncases or
controls) are randomly selected from those members of the same
population, or a specified subset of it, who are disease-free
during the case accession period. Information on the values of
explanatory variables during the time period prior to case or
control ascertainment is obtained at the time of ascertainment.
These retrospective data are usually subject to more error in
measurement than the prospective data of a cohort study; how-
ever, a case-control study can be completed more quickly. The
case-control design facilitates comparisons of disease rates in
different subsets of the study population but, since the numbers
of cases and controls sampled are fixed by the design, it cannot
provide an estimate of the actual disease rates. Case-control de-
signs vary in the degree of matching of cases to controls with
respect to disease risk factors other than the exposure under
study.
Most frequently, the analysis of case-control studies is based
on logistic regression with a binary outcome, Y, specifying dis-
ease status. If case-control data are analysed using a logistic
regression model, then although the estimate of the parameter a
has no practical value because disease incidence can not be
estimated, the estimation of odds ratios, through the b parame-
ters, can proceed in the usual fashion.
More recently, variations on the cohort and case-control de-
signs are being used. Some of these designs involve case-control
sampling, perhaps matched on time, from a prospective cohort.
In such a study, some data on risk factors may not be collected
until an individual is sampled. For example, if blood samples are
collected from all individuals in the cohort, blood tests or genetic 2016 The Authors. Published by Elsevier Ltd. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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matching on time, individuals may be sampled as controls at one
time point but become a case at a later time point. This is often
referred to as a nested case-control study.
A second type of study involves specifying a cohort within
which events of interest, such as disease diagnoses, may occur.
Then a random sample of cohort members is selected, and data
from these individuals are acquired. This data collection may be
done prospectively or retrospectively, depending on the ques-
tions of interest and the availability of data on this ‘subcohort’.
This subcohort provides the controls in the analysis, but may
include individuals who develop the disease of interest at some
point. Also collected are data on all, or a random sample of,
remaining individuals in the cohort who develop the disease.
This type of study is known as a case-subcohort study or simply
as a case-cohort study.
Some care is required in choosing and carrying out an
appropriate analysis of data collected during a nested case-
control design, case-cohort or other similar studies. However,
regression models remain the basis of the analysis.
A case-control or similar design can also address clinical
questions related to patients with particular medical conditions.
No additional methodological issues arise.
Diagnostic studies
To consider designs to look at the performance of a diagnostic
test, Table 2 provides some illustrative numbers to highlight the
main features. Assume that 200 individuals are sampled and that
40 of these are found to have a disease D through‘gold-standard’
testing or observation which is assumed to be completely accu-
rate. These 200 individuals are tested with a diagnostic test T of
interest and 32 of the 40 diseased and 40 of the 160 non-diseased
individuals test positive.
Two key calculations would be an estimate of the sensitivity,
which is the probability that a diseased individual tests positive,
and the specificity which is the probability that a non-diseased
individual tests negative. From Table 2, the estimate of sensi-
tivity is 32/40 ¼ 80% and that of specificity is 120/160 ¼ 75%.
While these two probabilities specify aspects of the diagnostic
test’s performance, the test’s usefulness is also influenced by the
prevalence of the disease in the population on which it is used.
Two quantities that reflect this are termed the predictive value of
a positive test, the probability that an individual with a positive
test has the disease, and the predictive value of a negative test,
the probability that an individual with a negative test does not
have the disease. Estimates of these quantities from Table 2
would be 32/72 ¼ 44.4% and 120/128 ¼ 93.8% respectively. ItIllustrative example of a study of diagnostic testing
DD DL
Tþ 32 40 72
T 8 120 128
40 160 200
Table 2
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necessarily translate into uniformly good predictive performance.
It follows that the value of the test may differ depending on the
population of interest and the relative importance of false positive
and false negative tests.
A study to assess a diagnostic test will generally aim to esti-
mate sensitivity and specificity to a required accuracy. Thus,
unlike the scenario of Table 2 where it was assumed that 200
individuals from the population of interest are sampled, it would
generally be better, if possible, to recruit separate samples of
diseased and non-diseased individuals of a required size.
A study of 100 diseased individuals and 100 non-diseased
individuals from the population reflected in Table 2 might
generate results as given in Table 3.
Based on a simple logistic regression model, the estimated
specificity from Table 2 would be 75% with a 95% confidence
interval (CI) of (67.7%, 81.1%). From Table 3 it would be 75%
with CI (65.6%, 82.5%). Similarly, the estimated sensitivity from
Table 2 would be 80% with CI (64.8%, 89.7%), whereas from
Table 3 it would be 80% with CI (71.0%, 86.7%). The common
total number of individuals in Tables 2 and 3 is simply for
illustration and in general the numbers of diseased and non-
diseased individuals can be specified independently. However,
it can be seen that while Table 3 generates a slightly wider CI for
specificity (because the number of non-diseased individuals is
slightly smaller) there is a considerable narrowing of the CI for
sensitivity.
The design of a diagnostic study should therefore be driven by
a desired accuracy for the estimated sensitivity and specificity.
Given an expected prevalence, the corresponding predictive
values of positive and negative tests can then be calculated. The
variation in predictive performance with prevalence can then be
seen or predictive performance can be assessed for an individual
from a population for which the prevalence is determined from
other sources.
The above discussion has presumed that the diagnostic test of
interest provides a simple yes/no test result. An alternative is that
the diagnostic test provides a continuousmeasurement, say X, and
a value c is to be chosen such that, if X is greater than c, the test will
be deemed positive and otherwise negative. Then the sensitivity
and specificity vary with the choice of c where as c increases,
specificity increases but sensitivity decreases. A plot of sensitivity
versus specificity as c varies is termed, for historical reasons, a
receiver-operator-characteristic (ROC) curve and the performance
of the diagnostic measure is sometimes defined in terms of the
shape of this curve. From a design perspective, the key factor will
still be the accuracy of sensitivity and specificity estimates.Second example of a study of diagnostic testing
DD DL
Tþ 80 22 102
T 20 78 98
100 100 200
Table 3
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